Dr Kaitin writes and speaks frequently on factors that contribute to the slow pace and high cost of pharmaceutical R&amp,D and the impact of efforts to speed the drug development process.

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.

While significant progress has been made in developing treatments for rare diseases—highlighted by the approval of over 800 drugs for orphan diseases since ...

How CDMOs are reshaping pharmaceutical partnerships through friendshoring, risk-sharing economics, and specialized development capabilities.

U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb ...

We came across a bullish thesis on ICON Public Limited Company (ICLR) on Substack by DeepValue Capital. In this article, we ...

The pharmaceutical trade is complicated ... of the way the business functions: Generic drugs don’t require high costs for research and development, but drug companies only profit if they ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines ...

During a recent panel discussion sponsored by Purdue University, industry leaders explain how the technology is revolutionizing drug development and production ...